Innovent Biologics (HK:1801) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Innovent Biologics has received approval from China’s National Medical Products Administration for its drug Dovbleron, a next-generation treatment for ROS1-positive non-small cell lung cancer. This marks the 13th addition to Innovent’s portfolio, highlighting the company’s commitment to innovative cancer therapies. The approval follows positive results from a pivotal Phase 2 trial, showcasing significant efficacy in patients.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.
